Application of Tetrodotoxin for Anesthetic and Pain Management
DOI:
https://doi.org/10.62051/2zqrbx31Keywords:
Tetrodotoxin; Pain management; Local anesthetic; Neuropathic pain; Clinical trials.Abstract
Tetrodotoxin (TTX) is a potent neurotoxin that is predominately sourced from marine animals, which serves a dual role as both a fatal toxin and a potential therapeutic compound. TTX functions by selectively binding to voltage-gated sodium channels (VGSCs), preventing sodium ions from entering nerve cells and thereby blocking action potential formation. While its toxicity can lead to severe outcomes like whole-body paralysis and even death, TTX’s unique mechanism of action creates possibilities for anesthetic use and pain management. Unlike traditional local anesthetics, TTX offers long-lasting effects with a lower risk of cardiac toxicity due to its selective binding. TTX can effectively manage chronic and neuropathic pain, including cancer-related and chemotherapy-induced pain, with relatively mild side effects when used at controlled doses. Combining TTX with drugs like bupivacaine has shown a synergistic impact, significantly extending pain relief duration while reducing potential toxicity. The lacks of an antidote for TTX necessitates strict dosing controls and further research to ensure safety. This research explores the mechanisms and safety considerations of TTX, and most importantly, its emerging applications will be analyzed.
Downloads
References
[1] D. Hwang, T. Noguchi, Tetrodotoxin Poisoning. ScienceDirect; Academic Press (2007).
[2] R. Chen, S. H. Chung, Mechanism of tetrodotoxin block and resistance in sodium channels, Biochemical and Biophysical Research Communications 446(1) (2014) 370-374.
[3] W. A. Catterall, Cellular and molecular biology of voltage-gated sodium channels, Physiological Reviews 72(4 Suppl) (1992) S15-48.
[4] K. Sekimoto, M. Tobe, S. Saito, Local anesthetic toxicity: acute and chronic management, Acute Medicine & Surgery 4(2) (2017) 152-160.
[5] C. H. King, S. S. Beutler, A. D. Kaye, et al. Pharmacologic Properties of Novel Local Anesthetic Agents in Anesthesia Practice, Anesthesiology Clinics 35(2) (2017) 315-325.
[6] S. A. Goldlust, M. Kavoosi, J. Nezzer, et al. Tetrodotoxin for Chemotherapy-Induced Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Dose Finding Trial, Toxins 13(4) (2021) 235.
[7] R. González-Cano, M. C. Ruiz-Cantero, M. Santos-Caballero, et al. Tetrodotoxin, a Potential Drug for Neuropathic and Cancer Pain Relief, Toxins 13(7) (2021) 483.
[8] K. Kwong, M. J. Carr, Voltage-gated sodium channels, Current Opinion in Pharmacology 22 (2015) 131-139.
[9] F. R. Nieto, E. J. Cobos, M. Á. Tejada, et al. Tetrodotoxin (TTX) as a Therapeutic Agent for Pain, Marine Drugs 10(2) (2012) 281-305.
[10] N. A. Hagen, K. M. Fisher, B. Lapointe, et al. An open-label, multi-dose efficacy and safety study of intramuscular tetrodotoxin in patients with severe cancer-related pain, Journal of Pain and Symptom Management 34(2) (2007) 171-182.
[11] J. Marcil, J. S. Walczak, J. Guindon, et al. Antinociceptive effects of tetrodotoxin (TTX) in rodents, British Journal of Anaesthesia 96(6) (2006) 761-768.
[12] D. S. Kohane, J. Yieh, N. T. Lu, et al. A Re-examination of Tetrodotoxin for Prolonged Duration Local Anesthesia, Anesthesiology 89(1) (1998) 119-131.
[13] Y. Li, T. Ji, M. Torre, et al. Aromatized liposomes for sustained drug delivery, Nature Communications 14(1) (2023) 6659.
Downloads
Published
Conference Proceedings Volume
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.







